217 related articles for article (PubMed ID: 18724074)
1. Anti-IgE antibody therapy for Japanese cedar pollinosis: omalizumab update.
Okubo K; Nagakura T
Allergol Int; 2008 Sep; 57(3):205-9. PubMed ID: 18724074
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis.
Okubo K; Ogino S; Nagakura T; Ishikawa T
Allergol Int; 2006 Dec; 55(4):379-86. PubMed ID: 17130680
[TBL] [Abstract][Full Text] [Related]
3. Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated.
Ogino S; Nagakura T; Okubo K; Sato N; Takahashi M; Ishikawa T
Int Arch Allergy Immunol; 2009; 149(3):239-45. PubMed ID: 19218816
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis.
Nagakura T; Ogino S; Okubo K; Sato N; Takahashi M; Ishikawa T
Clin Exp Allergy; 2008 Feb; 38(2):329-37. PubMed ID: 18070163
[TBL] [Abstract][Full Text] [Related]
5. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy.
Kopp MV; Hamelmann E; Bendiks M; Zielen S; Kamin W; Bergmann KC; Klein C; Wahn U;
Pediatr Allergy Immunol; 2013 Aug; 24(5):427-33. PubMed ID: 23799935
[TBL] [Abstract][Full Text] [Related]
6. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.
Casale TB; Condemi J; LaForce C; Nayak A; Rowe M; Watrous M; McAlary M; Fowler-Taylor A; Racine A; Gupta N; Fick R; Della Cioppa G;
JAMA; 2001 Dec; 286(23):2956-67. PubMed ID: 11743836
[TBL] [Abstract][Full Text] [Related]
7. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis.
Nayak A; Casale T; Miller SD; Condemi J; McAlary M; Fowler-Taylor A; Della Cioppa G; Gupta N
Allergy Asthma Proc; 2003; 24(5):323-9. PubMed ID: 14619332
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis.
Kuehr J; Brauburger J; Zielen S; Schauer U; Kamin W; Von Berg A; Leupold W; Bergmann KC; Rolinck-Werninghaus C; Gräve M; Hultsch T; Wahn U
J Allergy Clin Immunol; 2002 Feb; 109(2):274-80. PubMed ID: 11842297
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab: a monoclonal anti-IgE antibody.
Belliveau PP
MedGenMed; 2005 Jan; 7(1):27. PubMed ID: 16369332
[TBL] [Abstract][Full Text] [Related]
10. [Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].
Kupryś-Lipińska I; Kuna P
Pneumonol Alergol Pol; 2009; 77(1):43-51. PubMed ID: 19308909
[TBL] [Abstract][Full Text] [Related]
11. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
Holgate ST; Djukanović R; Casale T; Bousquet J
Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
[TBL] [Abstract][Full Text] [Related]
12. Seasonal omalizumab reduces allergen-specific immunoglobulin E levels in patients with Japanese cedar pollinosis and asthma.
Hamada S; Yasuba H
Rev Port Pneumol (2006); 2017; 23(6):365-367. PubMed ID: 29042155
[No Abstract] [Full Text] [Related]
13. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis.
Stock P; Rolinck-Werninghaus C; Wahn U; Hamelmann E
BioDrugs; 2007; 21(6):403-10. PubMed ID: 18020623
[TBL] [Abstract][Full Text] [Related]
14. Anti-immunoglobulin E (omalizumab) therapy in seasonal allergic rhinitis.
Casale TB
Am J Respir Crit Care Med; 2001 Oct; 164(8 Pt 2):S18-21. PubMed ID: 11704613
[TBL] [Abstract][Full Text] [Related]
15. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
[TBL] [Abstract][Full Text] [Related]
16. Anti-IgE therapy with omalizumab in asthma and allergic rhinitis.
Dodig S; Richter D; Cepelak I; Benko B
Acta Pharm; 2005 Jun; 55(2):123-38. PubMed ID: 16179127
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
[TBL] [Abstract][Full Text] [Related]
18. Role of immunmodulators in allergen-specific immunotherapy.
Kopp MV
Allergy; 2011 Jun; 66(6):792-7. PubMed ID: 21332502
[TBL] [Abstract][Full Text] [Related]
19. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis.
Kim DH; Park KY; Kim BJ; Kim MN; Mun SK
Clin Exp Dermatol; 2013 Jul; 38(5):496-500. PubMed ID: 23083013
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab: an effective anti-IgE treatment for allergic asthma and rhinitis.
Casale TB;
Drugs Today (Barc); 2004 Apr; 40(4):367-76. PubMed ID: 15190389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
